Navigation Links
JDRF-funded clinical trial demonstrates continuous glucose monitoring improves blood sugar control
Date:9/8/2008

ts (p<0.001); improvements in secondary measurements were also significantly greater in CGM patients, including the percentage of patients able to achieve an HbA1c level below 7%, or a 10% relative or 0.5% absolute drop in HbA1c. The improvement in HbA1c occurred without an increase in hypoglycemia (low blood sugar), which is the worry when attempting to tighten glucose control. In children aged 8-14 years old, the average decrease in HbA1c was not significantly different in the CGM and control groups; however, those in the CGM group were more likely to lower their HbA1c by at least 10% and achieve HbA1c levels below 7% compared with the control group. Fifteen-to-24-year-old CGM patients, as a group did not experience significant improvements in glucose control compared with the control group.

CGM use varied with age, averaging at least six days a week over the course of the trial in 83% of the patients 25 years and older, but dropping off to 30% of the 15 to 24 year olds and 50% of the 8 to 14 year olds (for whom CGM use typically involved their parents' assistance). Although the study was not specifically designed to assess the effect of frequency of CGM use on HbA1c, an analysis presented at EASD suggested that patients within all three age groups, including teens and young adults, who used the device at least six days a week had substantially lower HbA1c levels after six months compared with patients who used CGM less than six days a week.

"These results are very important, because they show that continuous glucose monitors are more than simply devices of convenience for people with diabetes they are tools that can substantially improve blood sugar control when used regularly," said Dr. Aaron Kowalski, Program Director for Metabolic Control at JDRF. "Based on the findings of previous studies, better control of glucose levels over the long term can be expected to translate to a lower risk of complications for people with Type 1 diabetes.
'/>"/>

Contact: Jillian Lubarsky
jlubarsky@jdrf.org
212-479-7626
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. New study spotlights National Institutes of Health grant outcomes for clinical research
2. NCI grant launches clinical trials for colon cancer screening
3. Florida researchers receive JDRF Excellence in Clinical Research Award
4. A nutritional supplement could improve the clinical situation of ICU patients
5. NIH expands national consortium dedicated to transforming clinical and translational research
6. Peter J. McGuire, MB BCh, is awarded the 2008-2009 Genzyme/ACMGF Clinical Genetics Fellowship
7. Clinical trial that may help patients breathe easier begins at Central DuPage Hospital
8. The Lancet publishes first clinical trial data of a fully bioabsorbable drug eluting stent
9. NHLBI issues first US von Willebrand Disease clinical practice guidelines
10. Simple screening questionnaire for kidney disease outperforms current clinical practice guidelines
11. Nucleonics initiates hepatitis B clinical trial with expressed interfering RNA therapeutic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) ... Chemical Sensor Market 2015-2019" report to their ... One major trend upcoming in this ... in biomedical applications. Chemical sensors help in recording ... during surgical procedures. The Global Chemical Sensor market ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... category for the largest human-designed protein, then a team of ... have designed and successfully synthesized a variant of a protein ... It is more than twice the size of the previous ... of Washington in 2003. The synthetic protein, designated FLR, ...
... A study conducted by researchers at the Johns Hopkins ... patterns of drug resistance in malaria-causing parasites taken from ... in human blood samples showed a high prevalence for ... widely used to treat malaria in the region. However, ...
... CHAPEL HILL, N.C. After a heart attack, the portions ... scar tissue. Researchers have long sought ways to avoid this ... its ability to pump blood throughout the body and eventually ... of North Carolina at Chapel Hill School of Medicine shows ...
Cached Biology News:Creation of the largest human-designed protein boosts protein engineering efforts 2Creation of the largest human-designed protein boosts protein engineering efforts 3Contrasting patterns of malaria drug resistance found between humans and mosquitoes 2Scarring a necessary evil to prevent further damage after heart attack 2
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of the ... Maroulis, Pharm.D. to the newly created position of Vice ... position, Dr. Maroulis will continue to manage the entire ... multi-site pharmacies as the company expands. Dr. Maroulis has ... he has served in many different capacities in the ...
Breaking Biology Technology:Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2
... fight cancer, rheumatoid arthritis, as well as enhance ... CEL-SCI Corporation (NYSE Amex: CVM ) ... 11th annual National Foundation of Infectious Diseases Conference ... L.E.A.P.S.(TM) (Ligand Epitope Antigen Presentation System) vaccine technology ...
... April 27 MannKind Corporation (Nasdaq: MNKD ... on Monday, May 4, 2009.Management of the Company will ... financial results and other Company developments at 4:00 PM ... will be its Chairman and Chief Executive Officer, Alfred ...
... SAN DIEGO, April 27 Cadence Pharmaceuticals, Inc. (Nasdaq: ... clinical trials of its investigational product candidate, Acetavance(TM) (intravenous ... Regional Anesthesia and Pain Medicine (ASRA) 34th Annual Regional ... and at the Society of Hospital Medicine (SHM) Annual ...
Cached Biology Technology:CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease 2CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease 3CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease 4MannKind Corporation to Hold First Quarter Financial Results Conference Call on May 4, 2009 2Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences 2
... DNA Polymerase is a premium quality recombinant ... thermostable enzyme is suitable for a wide ... highest purity and reproducible performance, each preparation ... quality control assays. NovaTaq DNA Polymerase possesses ...
... cell sorter sets a new standard for ... a revolutionary new design in instrumentation, this ... multicolor analysis. The BD FACSAria instrument is ... fixed-alignment cuvette flow cell. This new ...
Mouse monoclonal antibody raised against a partial recombinant COG2. NCBI Entrez Gene ID = COG2...
Mouse polyclonal antibody raised against a partial recombinant IFNA13. NCBI Entrez Gene ID = 3447...
Biology Products: